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Background: Patients with chronic obstructive pulmonary disease (COPD) have a higher risk 
of stroke than the general population. Chronic inflammation associated with COPD is thought 
to contribute to this risk. Exacerbations of COPD are associated with a rise in inflammation, 
suggesting that there may be an association between exacerbation frequency and the risk of 
stroke. This study examined that association.
Methods: Using the UK Clinical Practice Research Datalink, COPD patients with a first stroke 
between January 2004 and December 2013 were identified as cases and matched on age, sex, 
and general practice to controls with COPD but without a stroke (6,441 cases and 19,323 con-
trols). Frequent exacerbators (FEs) were defined as COPD patients with $2 exacerbations, and 
infrequent exacerbators (IEs) have #1 exacerbation in the year prior to their stroke. Conditional 
logistic regression was used to estimate the association between exacerbation frequency and 
stroke overall, and by stroke subtype (hemorrhagic, ischemic, or transient ischemic attack). Exac-
erbations were also categorized into 0, 1, 2, or $3 exacerbations in the year prior to stroke.
Results: There was no evidence that FE had an increased odds of stroke compared to IE (OR 
[odds ratio] =0.95, 95% CI [confidence interval] =0.89–1.01). There was strong evidence that the 
risk of stroke decreased with each exacerbation of COPD experienced per year (P
trend
 =0.003). 
In the subgroup analysis investigating stroke subtype, FE had 33% lower odds of hemorrhagic 
stroke than IE (OR =0.67, 95% CI =0.51–0.88, P=0.003). No association was found within 
other stroke types.
Conclusion: This study found no evidence of a difference in the odds of stroke between IE and 
FE, suggesting that exacerbation frequency is unlikely to be the reason for increased stroke risk 
among COPD patients. Further research is needed to explore the association through investigation 
of stroke risk and the severity, duration, treatment of exacerbations, and concurrent treatment 
of cardiovascular risk factors.
Keywords: COPD exacerbations, stroke, frequent exacerbators, infrequent exacerbators
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by inflammation of 
the small airways and lung parenchyma, which leads to progressive airflow limitation.1 
By 2020, COPD is expected to be the third most common cause of death worldwide.2 
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in COPD 
patients, with lung cancer and CVD being the commonest causes of death in patients 
with moderate COPD.1,3
Stroke is the second leading cause of death worldwide and the most important 
cause of acquired disability in most parts of the world.4 The prevalence and incidence 
of stroke are higher in COPD patients than in the general population.5,6
Atherosclerosis is the common underlying pathological process in the develop-
ment of the majority of ischemic strokes, with the strongest risk factors for stroke of 
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any type being hypertension and smoking.4 Local lung and 
systemic inflammation have been shown to accelerate the 
process of atherosclerosis, and inflammation is an indepen-
dent risk factor for CVD.1–4 Not only is COPD itself a raised 
inflammatory state, exacerbations of COPD are associated 
with acutely increased periods of both lung and systemic 
inflammation.7 The resulting acute inflammatory changes 
may correspond to a temporary rise in the risk of stroke. In 
a self-controlled case series of 25,875 COPD patients carried 
out within a UK primary care database, there was a 1.26-fold 
(95% CI [confidence interval] =1.0–1.6) increased risk of 
stroke 1–49 days after an exacerbation.8 Frequent exacerba-
tors (FEs) of COPD,9 people who have two or more health 
care utilization exacerbations per year, have increased airway 
and systemic inflammation, even in the stable state. They 
also have been shown to have increased arterial stiffness,10 
which is a validated, independent risk factor for cardiovas-
cular events.11 While there is no published literature to date 
on exacerbation frequency and risk of stroke, there are at 
least two potential mechanisms by which FE could have an 
increased risk of stroke, and there is evidence that history of 
stroke is more common in FE.12
Using data from the Clinical Practice Research Datalink 
(CPRD), we undertook a matched case control study to 
determine if the risk of stroke varied within COPD patients 
according to the number of exacerbations they experienced. 
Our specific objectives were: 1) to estimate the association 
between exacerbation frequency and stroke risk, 2) to deter-
mine if there was a dose–response relationship between the 
number of exacerbations per year and the risk of stroke, and 
3) to determine if this varied by stroke subtype; hemorrhagic, 
ischemic, or transient ischemic attack (TIA).
Methods
Data source
CPRD is the world’s largest validated computerized database 
of anonymized longitudinal medical records for primary 
care.13,14 Data comprise approximately 14 million patients 
from 660 primary care practices spread throughout the UK. 
Records are derived from a widely used general practice (GP) 
software system and contain complete prescribing data, and 
Read-coded diagnostic and clinical information as well as 
information on tests requested, laboratory results, and refer-
rals made at or following on from each consultation.15 The 
population of patients within CPRD have been shown to be 
representative of the UK population with respect to age, sex, 
and geographical distribution.16
study population
The study population consisted of patients over 35 years old, 
with a validated diagnosis of COPD.17
Primary outcome
Cases were all individuals in the study population who expe-
rienced a stroke between January 1, 2004 and December 31, 
2013. Validated diagnostic Read codes were used to define 
stroke.18 The primary outcome was created by group-
ing any event with a diagnostic Read code for ischemic/
hemorrhagic/nonspecific stroke or TIA. The secondary out-
come was type of stroke, which was coded as either ischemic, 
hemorrhagic, or TIA. Patients were excluded if they had a 
previous stroke or TIA in their CPRD record, were not regis-
tered with CPRD at the time of their stroke, or had less than 
1 year of standard follow-up prior to the date of stroke.
Three controls per case were selected from the study 
population, on the date of the stroke in the case (index date). 
Controls were matched to cases for age (within 5 years), sex, 
and GP. Inclusion and exclusion criteria for the controls 
were the same as those for cases (using index date instead 
of stroke date to define eligibility). Controls were eligible to 
become cases later during their follow-up and were allowed 
to be used as a control for more than one case.
Defining COPD exacerbations
An exacerbation of COPD was defined using a validated 
definition as an episode that was recorded in CPRD using 
Read codes as an acute exacerbation of COPD code or a 
lower respiratory tract infection (LRTI) code where antibi-
otics and/or oral steroids were also issued on the same day 
as the LRTI code.19
The number of exacerbations in the year prior to the 
index date was categorized in two ways. For the first analy-
sis, “frequent exacerbators” were defined as individuals 
with $2 recorded exacerbations in the year prior to the index 
date, while “infrequent exacerbators” were individuals who 
had #1 exacerbation in the year prior to the index date. 
Second, exacerbation frequency was grouped into 0, 1, 2, 
or $3 exacerbations in the previous year.
Covariates
Possible confounders were extracted from CPRD and 
included demographic factors (age [categorized into four 
age-bands; 35–59, 60–69, 70–79, and $80 years], sex, 
ethnicity, BMI [body mass index; using World Health 
Organization classification]), comorbid cardiovascular 
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disease (angina, heart failure, previous coronary intervention 
[percutaneous coronary intervention or coronary artery 
bypass graft {CABG}], peripheral arterial disease, acute 
coronary syndrome, myocardial infarction, angina), stroke 
risk factors (hypertension, diabetes, dyslipidemia, family 
history of cardiovascular or cerebrovascular disease, smok-
ing history [current, ex, or never], atrial fibrillation), and 
drug prescriptions (antiplatelets, anticoagulants, statins, 
angiotensin-converting enzyme inhibitors, angiotensin recep-
tor blockers, nitrates, calcium channel blockers, β-blockers). 
For all medications, a patient was considered exposed if 
their record contained at least two prescriptions of the same 
medication prior to the index date. The Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) 2011 staging 
system was used to define COPD severity with respect to 
airflow limitation.20 Code lists for all covariates are avail-
able on request.
statistical analysis
Conditional logistic regression was used to compare the odds 
of stroke in “frequent” and “infrequent” exacerbators. Causal 
modeling was performed using DaGitty software.21 Smoking 
status was an a priori confounder, and age and sex were con-
sidered as a priori effect modifiers. Any variable which was 
related to both COPD exacerbations and stroke was included. 
Other variables were added sequentially. Variables taken for-
ward to the full model were identified using a causal modeling 
approach, clinical knowledge, or they were identified from 
the univariable analysis, having been strongly associated 
with stroke, or deemed of sufficient priori interest to include. 
Conditional logistic regression, including interaction terms, 
was used to assess interaction between exacerbation frequency 
and age, as well as exacerbation frequency and sex. To exam-
ine the association between exacerbation frequency and stroke 
subtype, we repeated the analysis in a dataset restricted to 
1) ischemic stroke, 2) hemorrhagic stroke, and 3) TIA. For 
each subtype we performed conditional logistic regression, 
adjusting for the confounding factors identified in the primary 
analysis. Finally, to explore a dose–response relationship 
between exacerbation frequency and stroke, we repeated the 
primary analysis using exacerbation frequency defined as 0, 
1, 2, or $3 exacerbations in the year prior to index date.
sensitivity analysis
To explore the impact of missing data on the analysis, a 
sensitivity analysis was carried out for variables with large 
amounts of missing values. Fully adjusted conditional 
regression models with and without the variable were com-
pared in complete case analyses.
Power calculation
The prevalence of FE among all COPD patients was 29% 
in a previous UK study.9 Taking this value as the estimated 
prevalence of FE in the controls, with 6,441 cases and 
19,323 matched controls, this study would have a power 
of greater than 90% to detect a minimum odds ratio (OR) 
greater than 1 (1.11) and a maximum OR less than 1 (0.9) 
with an α of 0.05.
ethics
Ethical approval was obtained from the local LSHTM ethics 
committee (ref 7448) as well as the Independent Scientific 
Advisory Committee (ISAC), (protocol 14_100).
Results
The final dataset consisted of 6,441 cases and 19,323 
controls. The study population consisted of more men than 
women (53.9% vs 46.1%). The median age of the population 
was 76 years (interquartile range: 69–82). Approximately 
26.8% (1,723/6,441) of cases were FE compared to 28% 
(5,430/19,323) of controls (OR =0.93, 95% CI =0.87–0.99). 
Hypertension, smoking, dyslipidemia, and diabetes were all 
strongly associated with increased odds of stroke (Table 1). 
There were also strong associations between stroke and 
peripheral arterial disease, heart failure, atrial fibrillation, 
and previous use of cardiac medications (Table 1). There 
was a strong association between GOLD stage and stroke 
(P=0.002), with the odds of stroke decreasing with increasing 
COPD grade severity.
association between exacerbation 
frequency and all stroke type
Approximately 26.8% (1,722/6,431) of cases were FE 
compared to 28.1% (5,428/19,292) of controls. There 
was no difference in the odds of stroke after adjusting for 
matched variables and smoking in FE and IE; (OR =0.94, 
95% CI =0.88–1.00). After adjusting for age, sex, GP, 
smoking status, diabetes, hypertension, dyslipidemia, heart 
failure, CABG prior to stroke, atrial fibrillation, peripheral 
arterial disease, β-blockers, and calcium channel blockers, 
there was no evidence of an association between exacer-
bation frequency and the odds of stroke (OR =0.95, 95% 
CI =0.89–1.01, P=0.09) (Table 2). There was no evidence that 
the association between exacerbation frequency and stroke 
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Table 1 Baseline characteristics and univariable analysis of association with stroke
Characteristic Cases (%), n=6,441 Controls (%), n=19,323 OR (95% CI)a
Male 3,473 (53.9) 10,419 (53.9)
age, mean years ± sD 74.9 (9.2) 74.8 (9.1)
Frequent exacerbators 1,723 (26.8) 5,430 (28.1) 0.93 (0.87–0.99)
gOlD staging (n=22,272)
1 880 (13.7) 2,639 (13.7) 1
2 2,777 (43.1) 8,351 (43.2) 0.98 (0.90–1.08)
3 1,407 (21.8) 4,754 (24.6) 0.87 (0.79–0.97)
4 320 (5.0) 1,144 (5.9) 0.82 (0.70–0.96)
smoking status (n=25,723)
never smoked 627 (9.7) 2,062 (10.7) 1
ex-smoker 2,776 (43.1) 8,806 (45.6) 1.04 (0.94–1.15)
Current smoker 3,028 (47) 8,424 (43.6) 1.20 (1.08–1.33)
Body mass index (n=24,999)
20 917 (14.8) 2,516 (13.4) 1
20–25 1,999 (31.2) 5,964 (31.8) 0.92 (0.84–1.01)
25–30 1,948 (31.3) 6,078 (31.5) 0.87 (0.80–0.96)
30 1,354 (21.8) 4,223 (22.5) 0.87 (0.79–0.96)
stroke risk factors
Positive family history 1,615 (25.1) 4,688 (24.3) 1.05 (0.98–1.12)
Dyslipidemia 1,374 (21.3) 3,810 (19.7) 1.12 (1.04–1.20)
hypertension 3,448 (53.5) 9,374 (48.5) 1.24 (1.17–1.31)
Diabetes 1,157 (18.0) 2,951 (15.27) 1.22 (1.13–1.32)
Cardiovascular disease
PCI 202 (3.1) 514 (2.7) 1.19 (1.01–1.40)
PaD 724 (11.2) 1,503 (7.8) 1.51 (1.37–1.66)
acute coronary syndrome 50 (0.8) 113 (0.6) 1.33 (0.95–1.86)
MI 746 (11.6) 1,970 (10.2) 1.16 (1.06–1.26)
heart failure 895 (13.9) 2,317 (12.0) 1.19 (1.09–1.30)
CaBg 239 (3.7) 589 (3.1) 1.24 (1.06–1.44)
angina 1,142 (17.8) 3,163 (16.4) 1.10 (1.02–1.19)
Atrial fibrillation 1,064 (16.5) 2,146 (11.1) 1.61 (1.48–1.75)
Cardiac medications
β-blocker 2,170 (33.7) 5,240 (27.1) 1.38 (1.30–1.47)
aCe inhibitor 3,017 (46.8) 8,051 (41.7) 1.24 (1.17–1.32)
angiotensin II inhibitor 1,076 (16.7) 2,732 (14.1) 1.23 (1.14–1.33)
nitrate 1,338 (20.7) 3,717 (19.2) 1.10 (1.03–1.18)
Calcium channel blocker 2,174 (33.8) 5,752 (29.8) 1.21 (1.14–1.29)
lipid lowering medication 3,217 (50.0) 8,503 (44) 1.30 (1.22–1.37)
antiplatelet 3,831 (59.5) 8,782 (45.5) 1.82 (1.71–1.93)
anticoagulant 847 (13.2) 2,137 (11.1) 1.22 (1.12–1.32)
Note: aadjusted for age, sex, and gP.
Abbreviations: OR, odds ratio; CI, confidence interval; SD, standard deviation; GOLD, Global Initiative on Obstructive Lung Disease; PCI, percutaneous coronary 
intervention; PaD, peripheral arterial disease; MI, myocardial infarction; CaBg, Coronary artery Bypass graft; aCe, angiotensin-converting enzyme; gP, general practice.
Table 2 Multivariable analysis of the odds of stroke and type of stroke, comparing COPD patients with frequent exacerbations to 
those with infrequent exacerbations
Stroke type Exacerbation frequency Cases (%) Controls (%) Crude ORa (95% CI) Adjusted ORb (95% CI)
all stroke n=6,431 n=19,292
Infrequent 4,709 (73.2) 13,864 (71.9) 1 1
Frequent 1,722 (26.8) 5,428 (28.1) 0.94 (0.88–1.00) 0.95 (0.89–1.01)
Ischemic n=1,262 n=3,786
Infrequent 944 (74.8) 2,769 (73.1) 1 1
Frequent 318 (25.2) 1,017 (26.9) 0.93 (0.79–1.07) 0.93 (0.81–1.08)
hemorrhagic n=420 n=1,260
Infrequent 331 (78.8) 900 (71.4) 1 1
Frequent 89 (21.2) 360 (28.6) 0.68 (0.52–0.88) 0.67 (0.51–0.88)
TIa n=2,457 n=7,371
Infrequent 1,758 (71.6) 5,254 (71.3) 1 1
Frequent 699 (28.5) 2,117 (28.7) 0.99 (0.89–1.09) 1.00 (0.90–1.11)
Notes: aadjusted for age, sex, gP, and smoking status, badjusted for age, sex, GP, smoking status, hypertension, diabetes, dyslipidemia, atrial fibrillation, heart failure, 
peripheral arterial disease, CaBg, calcium channel blockers, β-blockers.
Abbreviations: COPD, chronic obstructive pulmonary disease; OR, odds ratio; CI, confidence interval; TIA, transient ischemic attack; GP, general practice; CABG, 
coronary artery bypass graft.
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varied with age (LRT [likelihood ratio test] for interaction 
P=0.11) or sex (LRT for interaction P=0.57).
Dose–response relationship between number of 
exacerbations and risk of stroke
There was evidence of an association between number of 
exacerbations (grouped as 0, 1, 2, or $3 exacerbations 
in the year prior to index date) and stroke (all subtypes). 
Patients with three or more COPD exacerbations in the 
year prior to index date, had 15% lower odds of stroke than 
patients with no exacerbations (OR =0.85, CI =0.77–0.94). 
There was strong evidence for a linear trend after adjust-
ing for confounders (P
trend
 =0.003). The odds of stroke 
decreased by approximately 5% with each additional 
exacerbation per year (OR =0.95, 95% CI =0.92–0.98) 
(Figure 1).
association between exacerbation 
frequency and stroke subtypes
In a dataset limited to patients where cases had hemor-
rhagic stroke (n=420 cases, 1,260 matched controls), 21.2% 
(89/420) of cases were FE compared to 28.6% (360/1,260) 
of controls.
In multivariable analysis, there was strong evidence of an 
association between exacerbation frequency and hemorrhagic 
stroke. Patients with frequent exacerbations had 33% lower 
odds of hemorrhagic stroke than patients with infrequent 
exacerbations (OR =0.67, 95% CI =0.51–0.88). There was 
no evidence for an association with either ischemic stroke 
or TIA and frequent exacerbations (Table 2).
sensitivity analysis
With respect to missing data, 13.6% (3,492/25,764) of obser-
vations had missing data on GOLD staging, 3% (765/25,764) 
had missing data on BMI status, and 0.2% (41/25,764) had 
missing data on smoking status (Table S1). For all three vari-
ables, individuals with missing data were more likely to be 
over 80 years old, than individuals without missing data.
In a complete case analysis including adjustment for 
GOLD stage, there was no evidence of an association 
between exacerbation frequency and stroke (adjusted 
OR =0.96, 95% CI =0.90–1.03), the OR including GOLD 
stage was almost identical to the main analysis (crude 
OR =0.94, 95% CI =0.88–1.00, adjusted OR =0.95, 95% 
CI =0.89–1.01, P=0.09).
Discussion
Our analysis showed that FE of COPD had similar odds 
of stroke to IE. However, on further exploration of the 
association between exacerbations and stroke, we found 
the odds of stroke decreased by approximately 5% with 
each additional exacerbation per year. When investing the 
association between exacerbation frequency and risk of each 
stroke subtype, there was strong evidence that FE had 33% 
lower odds of hemorrhagic stroke than IE (OR =0.67, 95% 
CI =0.51–0.88, P=0.003). However, there was no evidence 
for an association with either ischemic stroke or TIA.
The reason we found no association between exacerbation 
frequency and risk of stroke, but a strong inverse association 
between exacerbation number and risk of stroke is likely due 
to the way in which exacerbation frequency was defined. 
Figure 1 association between number of COPD exacerbations per year and stroke.
Notes: *Adjusted for age, sex, GP, smoking, hypertension, diabetes, dyslipidemia, atrial fibrillation, CABG, PAD, heart failure, calcium channel blockers, β-blockers. 
Ptrend =0.003.
Abbreviations: OR, odds ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease; GP, general practice; CABG, coronary artery bypass graft; PAD, 
peripheral artery disease.
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In our primary analysis, we split the COPD patients into two 
groups ($2 exacerbations vs #1 exacerbation) such that the 
baseline group included patients with an exacerbation. In our 
secondary analysis, we split COPD patients into groups by 
exacerbation number (0, 1, 2, 3+), which allowed comparison 
to patients with no exacerbations as baseline.
Our findings are somewhat contradictory to a previous 
study which found increased stroke risk acutely after an 
exacerbation.8 However, that study only quoted risk for 
ischemic strokes/TIA, and the association was only sig-
nificant when exacerbations were defined as treatment with 
antibiotics (not with steroids alone or both). Additionally, 
the preferred definition of an exacerbation was not prestated, 
meaning that the study may have been more prone to Type-1 
error. Another self-controlled case series set in primary 
care database found an approximately threefold increase in 
incidence rate of stroke in the first 3 days following an acute 
respiratory tract infection (IR =3.19, 95% CI =2.81–3.62) 
in the general population.22 This is in-keeping with the 
Donaldson et al study,8 although the at-risk period for stroke 
following a respiratory tract infection was much shorter than 
the at-risk period found following a COPD exacerbation, and 
the strength of the association was greater.
There are two plausible reasons why a COPD patient 
with increasing numbers of exacerbations may have a lower 
risk of stroke. The first is that a treatment for exacerbations 
causes a reduction in stroke risk. Oral glucocorticoids have 
been shown to reduce stroke risk in other studies, both 
in patients with COPD and in patients with rheumatoid 
arthritis.23 Our study was unable to explore the effect of 
steroids, as taking steroids was part of the exposure defini-
tion, making the effects of the two impossible to disassociate. 
Equally, the use of inhaled corticosteroids, which are more 
commonly prescribed for FE, may offer a protective effect. 
This warrants further investigation. A second explanation 
is that by definition, each exacerbation resulted in contact 
with health care services, meaning that those with more exac-
erbations are seen or reviewed more regularly by a health 
care professional. This may result in better management of 
other risk factors for stroke, including hypertension, smok-
ing, and diabetes, for which there may have been residual 
confounding. While it is known that exacerbations are 
associated with increased mortality and therefore it could 
be argued that our findings are due to a healthy survivor 
effect, given that previous studies have shown associations 
between respiratory infections/exacerbations and stroke and 
the fact that FE exist across all stages of COPD severity, this 
is unlikely.8,22 The disproportionate reduction in the risk of 
hemorrhagic stroke, compared to other stroke types, may 
reflect the importance of hypertension as a risk factor for 
hemorrhagic stroke. The impact of more frequent contacts 
with the GP and better opportunistic checking of blood pres-
sure, in patients with frequent exacerbations, may lead to 
better hemorrhagic stroke prevention than other subtypes. 
This merits further investigation.
Two large, key epidemiological studies have demon-
strated an increased risk of stroke in COPD patients, com-
pared to the general population.5,6 The first was an historical 
cohort study using data from patients registered in the 
Kaiser Permanente Medical Care Program.5 COPD patients 
had a higher risk of both hospitalization and death due to 
CVD (a composite measure, which included stroke). The 
risks were lower when looked at for stroke as an individual 
endpoint, and the association with stroke was weaker than 
all other measured endpoints (adjusted RR of death due to 
stroke was 1.25, CI =1.03–1.51). The study included 45,966 
COPD cases, followed up for 4 years, which was a key 
strength; however, there was no adjustment for smoking, 
and therefore residual confounding is likely to be a source 
of bias. The second study was a cross-sectional and cohort 
analysis comparing the prevalence and risk of CVD in 
patients with COPD to those without in a British primary 
care database.6 COPD patients had higher odds of prevalent 
CVD (OR =4.98, 95% CI =4.85–5.81) and stroke (OR =3.34, 
95% CI =3.21–3.48), as well as higher risk of incident CVD 
and stroke. In this study, CVD was a composite endpoint not 
including stroke. Despite this strong evidence for increased 
stroke risk in COPD patients, our study has shown that exac-
erbation frequency is unlikely to be driving the increased risk 
of stroke among COPD patients.
strengths
A key strength of our study was the size of the dataset; there 
was sufficient power to detect very small differences for 
the primary outcome. Matching on age, sex, and practice 
enhanced the precision of the estimated effects and allowed 
for some control of unmeasurable confounders related to 
which practice a patient belonged to, such as ease of access 
and prescribing practices.
The use of the specific diagnostic Read codes to identify 
patients with COPD has recently been validated.24 The 
definition of acute exacerbations of COPD has also been 
validated.19 A recent validation study of stroke codes used 
in CPRD showed that the positive predictive value of 75 
identified stroke codes was 89% (95% CI =87%–91%).18 
Data recorded in CPRD has been shown to be representative 
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of patients throughout the UK. Another strength of this study 
is that it is community based. Most patients with COPD are 
treated in the community, and most exacerbations of COPD 
are mild to moderate in severity. This means that the findings 
are generalizable to the majority of COPD patients treated 
in the community, across the UK.
limitations
All cases that occurred over the study period, in participating 
practices, were included, provided that they had presented to 
health services and been diagnosed as having a stroke. Some 
strokes may have occurred in patients who did not present to 
health care services; however, given the symptoms involved 
in a stroke, this is not likely to be a large number of cases. 
Some strokes may have resulted in death and not have been 
recorded with a diagnostic code in the medical records, but 
again this is likely to be a very small number. There was no 
information on how such missed cases would have differed 
from identified cases with respect to their exposure status; 
however, the overall impact in terms of bias is likely to be 
small.
Any health care utilization definition will miss unreported 
exacerbations. Exacerbations may also be misdiagnosed as 
other conditions with similar clinical presentations such as 
heart failure and pulmonary embolism. It is therefore likely 
that the number of exacerbations recorded in this study is an 
underestimate of the total number exacerbations experienced, 
which would lead to an underestimate of the association 
between frequent exacerbations and stroke.
Residual confounding could have resulted from unmea-
sured, incomplete measuring, or misclassification of con-
founders. Unmeasured risk factors for stroke include regular 
physical activity, alcohol intake, depression, and psychologi-
cal stress.4 Data for physical activity and alcohol intake were 
not extracted from CPRD because they were not recorded 
routinely. It would have been useful to look at the confound-
ing effect of depression and psychological stress, since both 
are more common in patients with chronic diseases, such 
as COPD, and may be increased in patients with frequent 
exacerbations.
The validity of the use of Read codes to define smoking 
is lower than the use of codes to define specific diagnoses, 
such as stroke or COPD.25 Current smoking tends to be well 
recorded, but previous smoking is not well recorded. In clini-
cal practice, ex-smokers tend to be misclassified as never 
smokers. This would lead to an underestimate of the number 
of ex-smokers, meaning that the OR for stroke were not fully 
adjusted for the effect of smoking.
Conclusion
This study found no evidence of a difference in the odds 
of stroke between COPD patients with low exacerbation 
frequency (0 or 1 per year) and those with high exacerba-
tion frequency (2 or more per year), and therefore exacer-
bation frequency is unlikely to be the reason for increased 
stroke risk among COPD patients. Furthermore, there was a 
decreased risk of stroke in COPD patients with an increas-
ing number of exacerbations. However, this association is 
likely to be more complex than exacerbation numbers alone 
and we recommend further exploration of this association 
through investigation of stroke risk and the severity, dura-
tion, treatment of exacerbations, and concurrent treatment 
of cardiovascular risk factors. The reduction, particularly in 
hemorrhagic stroke, associated with increased exacerbations 
of COPD is hypothesis generating and also warrants further 
investigation into the care and treatment received by patients 
experiencing exacerbations in GP.
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Table S1 Comparison of characteristics, between individuals with missing data and individuals without missing data
Characteristic Number of 
individuals with 
missing smoking 
status (%), 
(n=41)
Number of 
individuals 
without missing 
smoking status 
(%), (n=25,723)
Number of 
individuals 
with missing 
GOLD stage 
(%), (n=3,492)
Number of 
individuals 
without missing 
GOLD stage 
(%), (n=22,272)
Number of 
individuals 
with missing 
BMI (%), 
(n=765)
Number of 
individuals 
without 
missing BMI 
(%), (n=24,999)
stroke
Yes 10 (24.4) 6,431 (25.0) 1,057 (30.3) 5,384 (24.2) 223 (29.2) 6,218 (24.9)
no 31 (75.6) 19,292 (75) 2,435 (69.7) 16,888 (75.8) 542 (75.0) 18,781 (75.1)
exacerbations
Infrequent 38 (92.7) 18,573 (72.2) 2,736 (78.4) 15,875 (71.3) 593 (77.5) 18,018 (72.1)
Frequent 3 (7.3) 7,150 (27.8) 756 (21.7) 6,397 (28.7) 172 (22.5) 6,981 (27.9)
age (years)
35–59 0 (0) 1,744 (6.8) 179 (5.1) 1,565 (7.0) 27 (3.5) 1,717 (6.9)
60–69 1 (2.4) 5,806 (22.6) 512 (14.7) 5,295 (23.8) 85 (11.1) 5,722 (22.9)
70–79 7 (17.1) 9,785 (38.0) 1,138 (32.6) 8,654 (38.9) 229 (29.9) 9,563 (38.3)
$80 33 (80.5) 8,388 (32.6) 1,663 (47.6) 6,758 (30.3) 424 (55.4) 7,997 (40.0)
sex
Male 26 (63.4) 13,866 (53.9) 1,611 (46.1) 12,281 (55.1) 376 (49.2) 13,516 (54.1)
Female 15 (36.6) 11,857 (46.1) 1,881 (53.9) 9,991 (44.9) 389 (50.9) 11,483 (45.9)
Abbreviations: gOlD, global Initiative on Obstructive lung Disease; BMI, body mass index.
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